Finally, we speculate that relapse of AML after CIML NK cell therapy is associated with expression of NK inhibitory ligands, and may occur in the context of evasion of CD2-mediated activation in addition to other mechanisms that remain to be determined. The gene discussed is CD2; the disease is acute myeloid leukemia.